| Company/Division name | Generate Life Science |
| Type of work | Manufacturing |
| If manufacturing, is the company a contract manufacturer? | Yes |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2021 |
| Domestically, the work will be done: | In-house |
| City reshored to: | La Jolla |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | newborn stem cell biologics |
| What domestic positive factors made reshoring more attractive? | Higher productivity, Impact on domestic economy, Other, import replacement |
